• Riverwater Partners' Q1 2026 letter identifies Haemonetics (NYSE:HAE) as a top performance detractor for the quarter.
• The firm highlights renewed market share gains in plasma collection and improved confidence in Haemonetics' business fundamentals.
• The commentary follows a period of challenges in interventional cardiology and focuses on execution and market share trends.

Haemonetics, trading at about $59.93, has had a difficult stretch, with the share price down 25.1% year to date and 28.4% over three years. Over the past month, the stock shows a 7.2% return, and investor sentiment appears mixed as the market weighs recent setbacks alongside signs of improvement in core plasma operations.

For investors watching NYSE:HAE, Riverwater Partners' comments describe a story that centers on operational follow-through in plasma and stabilization in interventional cardiology. Upcoming quarters may be important for evaluating whether current market share gains and management's renewed confidence align with more consistent business fundamentals.

Stay updated on the most important news stories for Haemonetics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Haemonetics.

Riverwater Partners flagging Haemonetics as the top detractor after it was a top contributor just one quarter earlier underlines how quickly sentiment can swing when execution is in focus. The letter suggests the setback is tied less to a collapse in the core business and more to expectations resetting while investors watch whether plasma market share gains and pricing hold up. At the same time, Riverwater points to renewed traction in interventional cardiology after prior challenges, helped by investment in the commercial team and share gains starting to come through. For you as an investor, this reads as a vote of continued interest from an existing holder that is willing to sit through volatility as long as the plasma franchise and hospital technologies keep attracting customers, but it also highlights that the bar for execution is still high.

How This Fits Into The Haemonetics Narrative

• The focus on growing plasma collection volumes and favorable pricing lines up with the narrative that advanced systems like NexSys and related software are key drivers of share gains and margin improvement.
• References to earlier challenges in interventional cardiology test the assumption that targeted fixes in interventional technologies, including VASCADE, will translate into a durable recovery rather than just short bursts of share gains.
• The investor letter does not fully address longer term concerns around product and geographic concentration, which remain important in the narrative given Haemonetics’ reliance on a few U.S. centric franchises.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Haemonetics to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Heavy dependence on plasma and a handful of interventional products leaves earnings exposed if procedure trends, competition from peers like Baxter, Abbott, or Boston Scientific, or regulatory changes turn less favorable.
• ⚠️ Analysts have highlighted at least one financial risk, including a higher level of debt, which can matter if cash generation or pricing power in key franchises softens.
• 🎁 The letter’s emphasis on renewed plasma market share gains and improving confidence in fundamentals supports the view that core platforms still resonate with blood centers and hospitals.
• 🎁 Product updates such as expanded VASCADE MVP XL use and NexSys PCS with Persona PLUS, together with reported earnings growth and valuation support, give existing holders tangible operational milestones to track.

What To Watch Going Forward

From here, it makes sense to track whether plasma collection volumes and pricing continue to support revenue, and whether interventional cardiology share gains turn into steadier procedure growth. Watch commentary from investors like Riverwater around any changes in conviction, alongside updates on competition from larger medical-technology peers and Haemonetics’ progress in reducing reliance on a few U.S. focused products. The balance between using cash for buybacks, acquisitions, or debt management will also matter if volatility in the share price persists.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Haemonetics, head to the community page for Haemonetics to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.